|Catalyst Pharmaceutical Partners Inc.|
355 Alhambra Circle
United States - Map
Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
|Mr. Patrick J. McEnany ,
Co-Founder, Chairman, Chief Exec. Officer and Pres
|Ms. Alicia Grande CPA, CMA,
Chief Financial Officer, Chief Accounting Officer, VP and Treasurer
|Dr. Steven R. Miller Ph.D.,
Chief Operating Officer and Chief Scientific Officer
|Mr. David D. Muth ,
Exec. VP of Corp. Devel.
|Dr. Charles W. Gorodetzky M.D., Ph.D.,
Chief Medical Officer and Consultant
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|